X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (184) 184
humans (178) 178
hematology (109) 109
middle aged (105) 105
leukemia, myeloid, acute - genetics (101) 101
adult (97) 97
male (95) 95
female (93) 93
abridged index medicus (67) 67
prognosis (63) 63
aged (61) 61
oncology (57) 57
mutation (56) 56
adolescent (51) 51
cancer (45) 45
leukemia, myeloid, acute - mortality (41) 41
young adult (38) 38
leukemia (36) 36
aged, 80 and over (34) 34
mutations (34) 34
acute myeloid-leukemia (33) 33
treatment outcome (33) 33
acute myelogenous leukemia (30) 30
aml (30) 30
chromosome aberrations (29) 29
acute myeloid leukemia (28) 28
leukemia, myeloid, acute - pathology (28) 28
animals (27) 27
leukemia, myeloid, acute - drug therapy (27) 27
hemic and lymphatic diseases (26) 26
leukemia, myeloid, acute - therapy (26) 26
research (26) 26
nuclear proteins - genetics (24) 24
survival rate (24) 24
gene expression profiling (23) 23
fms-like tyrosine kinase 3 - genetics (22) 22
leukemia, myeloid, acute - metabolism (21) 21
mice (21) 21
gene expression regulation, leukemic (20) 20
leukemia, myeloid - genetics (20) 20
leukemia, myeloid, acute - diagnosis (20) 20
acute disease (19) 19
karyotyping (19) 19
prospective studies (19) 19
article (18) 18
expression (18) 18
gene expression (18) 18
group-b (18) 18
survival analysis (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
in situ hybridization, fluorescence (17) 17
internal tandem duplication (17) 17
kaplan-meier estimate (17) 17
cell biology (16) 16
disease-free survival (16) 16
younger adults (16) 16
adult patients (15) 15
cell line, tumor (15) 15
chemotherapy (15) 15
genetics & heredity (15) 15
mutation - genetics (15) 15
normal cytogenetics (15) 15
translocation, genetic (15) 15
biomarkers, tumor - genetics (14) 14
cohort studies (14) 14
dna mutational analysis (14) 14
myelodysplastic syndromes (14) 14
proto-oncogene proteins - genetics (14) 14
acute promyelocytic leukemia (13) 13
dna-binding proteins - genetics (13) 13
normal karyotype (13) 13
prognostic-significance (13) 13
cells (12) 12
cytogenetics (12) 12
favorable prognosis (12) 12
gene (12) 12
gene-expression (12) 12
risk factors (12) 12
transcription factors - genetics (12) 12
dna methylation (11) 11
gene expression regulation, neoplastic (11) 11
genetic aspects (11) 11
genomics (11) 11
leukemia, lymphocytic, chronic, b-cell - genetics (11) 11
oligonucleotide array sequence analysis (11) 11
proportional hazards models (11) 11
remission induction (11) 11
stem cells (11) 11
therapy (11) 11
trans-retinoic acid (11) 11
trial (11) 11
adults (10) 10
analysis (10) 10
biochemistry & molecular biology (10) 10
chromosome deletion (10) 10
classification (10) 10
follow-up studies (10) 10
gene deletion (10) 10
genes (10) 10
homeodomain proteins - genetics (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 7, pp. 601 - 612
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2016, Volume 22, Issue 7, pp. 792 - 799
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 18, pp. 1909 - 1918
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 08/2008, Volume 105, Issue 32, pp. 11299 - 11304
Telomere dysfunction limits the proliferative capacity of human cells by activation of DNA damage responses, inducing senescence or apoptosis. In humans,... 
Telomeres | Human aging | Enzyme activity | DNA damage | Stem cells | Cellular senescence | Chronic diseases | Bone marrow cells | Biological markers | Blood plasma | EF-1α | Senescence | CRAMP | Personalized therapy | stem cells | LIFE-SPAN | STEM-CELL FUNCTION | MULTIDISCIPLINARY SCIENCES | TISSUE | INTERLEUKIN-6 | CANCER | EF-1 alpha | senescence | MICE | MUTATIONS | SENESCENT FIBROBLASTS | MOUSE TELOMERASE | PULMONARY-FIBROSIS | personalized therapy | Cathelicidins | Gamma Rays - adverse effects | Apoptosis - radiation effects | Humans | Up-Regulation - radiation effects | Antimicrobial Cationic Peptides - biosynthesis | Male | Fibrosis - metabolism | Telomerase - genetics | Cellular Senescence - radiation effects | Female | Telomerase - metabolism | Telomere - metabolism | Peptide Elongation Factor 1 - biosynthesis | Fibroblasts - metabolism | Biomarkers - metabolism | Myelodysplastic Syndromes - metabolism | Bone Marrow Cells - pathology | Aging - radiation effects | Stathmin - biosynthesis | Chitinases - biosynthesis | Fibroblasts - pathology | Aging - pathology | Mice, Knockout | Telomere - pathology | Animals | Mice | Fibrosis - pathology | Myelodysplastic Syndromes - pathology | Bone Marrow Cells - metabolism | DNA Damage - radiation effects | Aging - metabolism | Cellular proteins | Chromatin | Aging | Genetic aspects | Research | Properties | Health aspects | Proteins | Tissue | Rodents | Cells | Deoxyribonucleic acid--DNA | Apoptosis | Index Medicus | Biological Sciences
Journal Article
Molecular Cancer, ISSN 1476-4598, 03/2013, Volume 12, Issue 1, pp. 19 - 19
Background: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including... 
PDGFR | Quizartinib | FLT3 | AC220 | Leukemia | KIT | WILD-TYPE | GASTROINTESTINAL STROMAL TUMOR | LIGAND-INDEPENDENT ACTIVATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | C-KIT | ACUTE MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROME | SYSTEMIC MASTOCYTOSIS | ONCOLOGY | FLT3 GENE | INTERNAL TANDEM DUPLICATIONS | MAST-CELL LEUKEMIA | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Phosphorylation | Apoptosis - drug effects | Humans | Apoptosis - genetics | Leukemia - metabolism | Proto-Oncogene Proteins c-kit - metabolism | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Dose-Response Relationship, Drug | fms-Like Tyrosine Kinase 3 - genetics | Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors | Inhibitory Concentration 50 | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Gastrointestinal Stromal Tumors - genetics | Leukemia - genetics | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Benzothiazoles - pharmacology | fms-Like Tyrosine Kinase 3 - metabolism | Receptor, Platelet-Derived Growth Factor alpha - genetics | Protein Isoforms | Cell Line, Tumor | Gastrointestinal Stromal Tumors - metabolism | Cell Proliferation - drug effects | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Mutation | Tyrosine | Medical research | Platelet-derived growth factor | Codon | Analysis | Medicine, Experimental | Phenols | Pediatrics | Hematology | Software | Kinases | Experiments | Drug dosages | Manuscripts | Index Medicus
Journal Article
Journal Article